[Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
D047228:Angiotensin II Type 1 Receptor Blockers; D001241:Aspirin / Q000627:therapeutic use*; D000068342:Aspirin, Dipyridamole Drug Combination; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D000077144:Clopidogrel; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy*; D000077333:Telmisartan; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D047228:Angiotensin II Type 1 Receptor Blockers; D000068342:Aspirin, Dipyridamole Drug Combination; D001562:Benzimidazoles; D001565:Benzoates; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin; D000077333:Telmisartan
Rezidivprophylaxe für Schlaganfall-Patienten. Welche Plättchenhemmer-Kombination schützt am besten?